Khloe Kardashian & Biohaven Migraine Drug to Product Team to Promote
Biohaven Pharmaceutical Company (BHVN) - Get the report together with reality-TV star Khloe Kardashian to promote Biopharma's Nurtec ODT migraine drug, the company said.
Shares of the New Haven, Conn., company at last check were 4.6% higher at $76.23.Sales of the tablet, generally known as rimegepant, in the first quarter were $1.2 million after the drug in February received Food and Drug Administration clearance.
Biohaven said in May that in the first full six weeks following launch, Nurtec ODT had the greatest week-over-week growth for new acute migraine treatments. More than 6,000 prescriptions have been written to date by more than 1,000 health-care providers.
Special Report: Download Jim Cramer's 5 Rules for Trading Stocks during the Earning Season - a set of practices that can help you survive the earnings season without losing too much money.
Bloomberg reported that Nurtec ODT received $ 50 million in revenue this year and topped $ 1 billion by 2024.Biohaven said that Nertech ODT reduces pain quickly, returns patients to normal function within an hour and, for many patients, lasts up to 48 hours.
Biohaven said that the World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. Migraine are characterized by debilitating attacks lasting four to 72 hours with multiple symptoms.
The company said 90% of migraine sufferers are unable to work or function normally during an attack.
Kardashian, who suffers from migraines, said in a statement that Nurtec ODT "worked fast and allowed me to get back to normal so that I could take back my day."
The reality star has been criticized for her past associations with certain weight-loss products.Biohaven faces competition in the migraine-treatment space from such companies as Amgen (AMGN) - Get Report, H. Lundbeck A/S, BLUE and Eli Lilly (LLY) - Get Report.
